- Home
- QNRX vs PALI Comparison
QNRX vs PALI Comparison
Compare QNRX & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- PALI
- Stock Information
- Founded
- QNRX 2018
- PALI 1996
- Country
- QNRX United States
- PALI United States
- Employees
- QNRX N/A
- PALI N/A
- Industry
- QNRX Medical/Dental Instruments
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNRX Health Care
- PALI Health Care
- Exchange
- QNRX Nasdaq
- PALI Nasdaq
- Market Cap
- QNRX 3.3M
- PALI 3.8M
- IPO Year
- QNRX N/A
- PALI N/A
- Fundamental
- Price
- QNRX $9.60
- PALI $0.70
- Analyst Decision
- QNRX
- PALI Strong Buy
- Analyst Count
- QNRX 0
- PALI 2
- Target Price
- QNRX N/A
- PALI $12.00
- AVG Volume (30 Days)
- QNRX 12.9K
- PALI 417.8K
- Earning Date
- QNRX 08-07-2025
- PALI 08-11-2025
- Dividend Yield
- QNRX N/A
- PALI N/A
- EPS Growth
- QNRX N/A
- PALI N/A
- EPS
- QNRX N/A
- PALI N/A
- Revenue
- QNRX N/A
- PALI N/A
- Revenue This Year
- QNRX N/A
- PALI N/A
- Revenue Next Year
- QNRX N/A
- PALI N/A
- P/E Ratio
- QNRX N/A
- PALI N/A
- Revenue Growth
- QNRX N/A
- PALI N/A
- 52 Week Low
- QNRX $5.01
- PALI $0.60
- 52 Week High
- QNRX $54.95
- PALI $4.89
- Technical
- Relative Strength Index (RSI)
- QNRX 64.78
- PALI 51.63
- Support Level
- QNRX $8.04
- PALI $0.60
- Resistance Level
- QNRX $8.58
- PALI $0.67
- Average True Range (ATR)
- QNRX 0.46
- PALI 0.05
- MACD
- QNRX 0.04
- PALI 0.01
- Stochastic Oscillator
- QNRX 98.57
- PALI 75.87
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.